Literature DB >> 15798381

Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era.

Rafael E Campo1, Carlos E Campo, Garnet Peter, Jessica Zuleta, Natalie A Wahlay, Timothy Cleary, Michael A Kolber, Gordon M Dickinson.   

Abstract

Invasive pneumococcal disease (PD) occurs frequently among HIV-infected patients, but it is unclear whether its manifestations and outcome are different compared to those observed among patients without HIV-1 infection. Because the immune reconstitution that accompanies antiretroviral therapy may change some of these features and because most cases of HIV- 1 infection occur in resource-poor settings of the world where access to antiretroviral agents is limited, we compared PD among patients with and without HIV-1 infection in a North American population before the introduction of highly active antiretroviral therapy (HAART). The records of all pneumococcal cultures processed at this medical center over a period of 20 months were used to identify patients with invasive PD. Hospital records were reviewed for 103 of these patients (52 with and 51 without HIV-1 infection) and demographic, clinical, laboratory, radiographic, and microbiologic information was abstracted and subsequently analyzed. Despite similarities in presenting signs and symptoms, we found a higher incidence of bacteremia but a more favorable outcome with less frequent requirements for intubation and admission to intensive care units and better survival among individuals with HIV infection. Factors such as less advanced age, the presence of fewer comorbid conditions, or a less florid inflammatory response among HIV-infected individuals may account for differences in outcome of invasive PD.

Entities:  

Mesh:

Year:  2005        PMID: 15798381     DOI: 10.1089/apc.2005.19.141

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  3 in total

Review 1.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

2.  Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014.

Authors:  Michal Chowers; Gili Regev-Yochay; Orna Mor; Ronit Cohen-Poradosu; Klaris Riesenberg; Oren Zimhony; Daniel Chemtob; Michal Stein; Ron Dagan; Itzchak Levy
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

3.  Antiretroviral Therapy as Prevention of … Pneumococcal Infections?

Authors:  Anaïs Lesourd; Jérémie Leporrier; Valérie Delbos; Guillemette Unal; Patricia Honoré; Manuel Etienne; Olivier Bouchaud; François Caron
Journal:  Open Forum Infect Dis       Date:  2016-12-20       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.